The MLL gene, encoding a transcription factor with histone H3 lysine 4 (H3K4) methyltransferase activity, is mutated via a gain-offunction intragenic, self-fusion mutation called the Partial Tandem Duplication (MLL-PTD) in B5% of patients with cytogenetically normal acute myeloid leukemia (CN-AML) and associates with poor prognosis. [1] [2] [3] [4] Although intense therapy such as postremission autologous or allogeneic stem cell transplant appears to improve their outcome, 5 adult patients with MLL-PTD-positive CN-AML still die of the disease, thus suggesting the need for novel 'personalized' treatment(s). Unfortunately, no specific inhibitors that target the aberrant MLL H3K4 methyltransferase activity are currently available. Nevertheless, we previously demonstrated an association of MLL-PTD with increased DNA hypermethylation, an epigenetic change mediated by DNA methyltransferases (DNMTs) that leads to aberrant tumor suppressor gene silencing in AML. We also showed that the combination of epigenetic targeting agents, a DNA hypomethylating agent (that is, decitabine) followed by a histone deacetylase inhibitor (HDACi), decreased the transcript ratio of the MLL-PTD-to-MLL-wild type (WT) alleles and concurrently induced apoptosis in MLL-PTD-positive blasts. 6 However, these results were obtained only with in vitro cultures, and as such, in vivo validation of this approach is necessary to move it into the clinic. Thus, we aimed herein to validate the epigenetics-targeting approach to MLL-PTD AML in an in vivo mouse model of spontaneous AML that harbors the knocked-in mutations of Mll-PTD and the receptor tyrosine kinase Flt3-internal tandem duplication (Flt3-ITD), hereafter referred to as double knock-in (dKI). This model recapitulates features of the counterpart human disease. 7 Indeed, B30% of MLL-PTD AML patients also harbor FLT3-ITD and have a poor prognosis. 5 The bone marrow (BM) from dKI AML mice exhibited an B1.7-fold increase in the global DNA methylation index, as measured using deep-sequencing analysis of methylated DNA captured by methyl-binding protein (MBD2) 8 ( Figure 1a , P ¼ 0.017, t-test, see Supplementary Material for all methods). Correspondingly, Dnmt1, 3a and 3b mRNA levels were increased in leukemia cells relative to single KIs or WT controls (1.5-, 2.3-and 5.3-fold, respectively, Pp0.0002) (Figures 1b-d) . These data establish that aberrant DNA hypermethylation occurred in the dKI AML model, thereby recapitulating epigenetic features of the human AML counterpart 6, 9 and supporting this model for in vivo targeting of aberrant epigenetics for the treatment of MLL-PTD-driven AML. Thus, we designed a study that combined a DNA hypomethylating agent, 5 0 -aza-2 0 -deoxycytidine (5AD), and a histone deacetylating agent AR42. 5AD is a nucleoside analog with a proven clinical activity in AML patients when given at a relatively low dose (20 mg/m 2 /day Â 10 days). 10 AR42 is a novel HDACi with a proven anti-leukemia activity that is being tested in an early clinical trial at our institution. [11] [12] [13] To establish optimal conditions and demonstrate anti-leukemia activity of the combination, we first tested AR42 in combination with 5AD on the MLL-PTD þ human EOL1 cell line, as well as on primary mouse dKI BM blasts cultured ex vivo in the presence of recombinant rat stem cell factor and murine interleukin-3. Cells were incubated with the sequential combination of 5AD followed by AR42, and exhibited significant growth inhibition and increased apoptosis ( Letters to the Editor Figure 2 . Epigenetic modifiers effectively target dKI blasts ex vivo and in vivo. (a-c) For the ex vivo studies, leukemic blasts were isolated from BM of dKI-leukemic mice and cultured with vehicle or 1-3 mM 5AD for 24 h followed by vehicle, 0.2 mM AR42 alone or 5AD plus AR42 for an additional 24 h. (a) MTS cell proliferation assays measured metabolic activity of the cells as indicated by % growth. (b) Flow cytometry was performed using Annexin V and 7AAD to detect apoptosis (AnnV þ /7AAD-). (c) Cdkn1a re-expression was determined by real-time reverse transcription PCR. (d-g) For in vivo studies, mice transplanted with dKI leukemia were treated with 0.2 mg/kg 5AD or vehicle intraperitoneal for 4 days followed by 50 mg/kg AR42 or vehicle every other day for 5 days (three doses total) via oral gavage (or the reverse sequence of AR42 followed by 5AD) upon demonstration of leukemia engraftment at 21 days post transplant. Early pharmacodynamic data were collected prior to the final dose of either 5AD or AR42 and included spleen weights (d), blood smears (e) and blast differentiation, as measured by acquisition of Gr1 via flow cytometry (f ). Each graph shows two different mice (six mice total). Vehicle-treated mice are in the shaded histograms. Each vehicle-treated mouse is overlaid with a different mouse treated with both 5AD and AR42 (black line). Clinical benefit was assessed by comparing (g) Kaplan-Meier survival curves of mice in the distinct treatment groups. Arrow indicates treatment initiation. Supplementary Figures S1A and S1B) . Furthermore, regulators of cell cycle arrest or differentiation were upregulated, driven by either AR42 alone (Rb and Ndrg1, Supplementary Figures S2A and S2B) or the combination of 5AD followed by AR42 (Cdkn1a, threefold increase in 5AD/AR42 compared with vehicle, P ¼ 0.026, Figure 2c) . Given that the Cdkn1a promoter exhibited hypermethylation in our leukemic BM compared with non-leukemic BM (data not shown), this release of silencing suggests appropriate epigenetic targeting of the drugs. Next, the drug combination was tested in vivo.
The primary dKI mice take B50-60 weeks to develop fatal leukemia. To ensure similar leukemia burden at the time of the treatment start, we serially transplanted whole spleen cells from primary leukemic mice into sublethally irradiated syngeneic recipients. This transplant model allowed us to reduce time to moribund state to B36 days. Treatment was started on day 21 post transplant, when mice had reached a white blood cell count 410.5 k/ml and engraftment was 470% donor cells in the blood, as measured by flow cytometry. 5AD (0.2 mg/kg daily intraperitoneal injection for a total of four doses) was either given before or after vehicle or AR42 (50 mg/kg delivered every other day via oral gavage for a total of three doses) to ascertain also whether the sequence impacted anti-leukemic activity in vivo. Prior to the last dose of treatment (either AR42 or 5AD, depending on the sequence), three mice were euthanized to assess early cytoreduction and pharmacodynamic endpoints. Because there was no significant difference in survival or pharmacodynamics endpoints between the sequences of 5AD followed by AR42 compared with AR42 followed by 5AD, results from these two studies were combined (5AD plus AR42). A reduction in leukemic load of Btwofold was measured by spleen weight (P ¼ 0.003; Figure 2d) , and a decrease in circulating blasts (Figure 2e ) was observed in mice treated with individual agents or the combination compared with vehicle-treated controls. No differences in reduction of tumor burden were observed between the different treatments or sequences at this time point. 5AD alone or the 5AD/AR42 combination induced differentiation of the blasts as measured by an increase in surface expression of CD11b (data not shown) and Gr1 (Figure 2f ), thereby supporting early anti-leukemia activity of these epigenetic modifiers either alone or in combination, as measured by cell differentiation rather than by cytotoxic effects. Nevertheless, the combination was more effective over time. Whereas mice treated with 5AD alone trended toward increased survival compared with vehicle-treated control mice (median survival 41 vs 36 days; P ¼ 0.10), and whereas AR42 showed a statistically significant increase in survival compared with vehicle controls (median survival 46 vs 36 days, Po0.0001; Figure 2g ), survival was further enhanced by the 5AD plus AR42 combination (median survival 54 days, P ¼ 0.004 for 5AD plus AR42 vs AR42 alone; Po0.0001 for 5AD plus AR42 vs 5AD alone; Po0.0001 for 5AD plus AR42 vs vehicle).
AML is a very heterogeneous disease and significant progress has been made over the past two decades in stratifying patients to more appropriate therapy based on molecular prognostic markers. In conjunction with the development of novel therapeutics comes the necessity for excellent, preclinical, mechanism-driven studies. Our murine dKI model of AML recapitulates the human disease and therefore represents an optimal model for testing cutting-edge therapies for MLL-PTD-positive AML. 7 Here we show that the leukemic mice responded early to all of these epigenetic modifiers by reversing epigenetic changes, provoking re-expression of otherwise silenced genes and inducing cell differentiation. However, the combination of the hypomethylating agent and the HDACi was more effective and provided a significantly longer survival than either agent alone. The reasons for the enhanced clinical benefit of the combination with respect to the single agents are unknown. It is possible that this is related to distinct but complementary sets of epigenetically silenced genes that are re-expressed by specific epigenetic treatment (for example, Rb and Ndrg1 vs Cdkn1a) and/or to an increased cytotoxic effect that emerges only when the hypomethylator and HDACi are combined. Nevertheless, our data support a rapid translation of the combined approach to the clinic.
Our basis for testing this therapy was our knowledge that both human and murine MLL-PTD þ AML exhibit DNA hypermethylation and dysregulation of tumor suppressors. However, tumor suppressor genes are epigenetically silenced in many AML subtypes-whether through dysregulation of DNA methylation or histone acetylationthus supporting use of this therapy on multiple AML subtypes. In fact, our recent work showed that expression of miR-29b, a negative regulator of DNMTs, was a predictor of success to single agent 5AD therapy on older patients (460yrs) with previously untreated AML (not specified by any particular subtype) who were not candidates for or who refused induction chemotherapy. 14 Furthermore, we showed that AR42 induces miR-29b, supporting the combination of 5AD plus AR42 in the clinic in a larger population of AML patients. 13 Studies of 5AD in combination of another HDACi, Valproic acid (VPA), have demonstrated only limited efficacy or doselimiting toxicity. 10, 15 A trial of 5AD with Vorinostat, a separate HDACi, is completed (ClinicalTrials.gov Identifier: NCT00357708), but findings have not yet been reported to our knowledge. AR42 fills a void by providing both higher specificity and higher efficacy than either VPA or Vorinostat both in vitro and in vivo. 12 Our findings that 5AD þ AR42 show significant efficacy in a powerful murine model of AML support the opening of a Phase I trial with this combination (ClinicalTrials.gov Identifier: NCT01798901).
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